- March 19, 2018 : Go Beyond Investing conducts due diligence on Primordial Genetics

Go Beyond Investing (https://go-beyond.biz/) is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.

The Go Beyond team has conducted a thorough non-technical due diligence of Primordial Genetics’ business model. The Go Beyond team worked with several experts in the field of synthetic biology to attain a high level of comfort regarding the technical and commercial viability of Primordial’s scientific innovation and bio-methionine first product. The due diligence process supported the commercial and market promise of Primordial’s technology and products in development. Go Beyond is prepared to make an initial investment in this company.

- Jan 1, 2018: Primordial Genetics receives NIH Grant: Synthetic biology E. coli strain development for expression of functional human GPCRs with roles in human disease

The principal aim of this project is to apply a novel synthetic biology approach to develop protein expression strains of the laboratory bacterium Escherichia coli that are suitable for producing functional G-protein-coupled receptor (GPCR) proteins.

GPCRs are diverse membrane proteins that are ubiquitous in the human body. They are involved in many physiological processes as well as many diseases and have been the most important drug targets in modern medicine. Efficient production of milligram quantities of functional GPCR is currently very difficult. Although E. coli is widely used for protein production, expressing functional GPCRs in E. coli is still challenging.

The novel E. coli expression host to be developed in this project will ignificantly accelerate the production of GPCRs and drug development work with this important class of human proteins. This project will not only have a broad impact in drug discovery across many diseases but also will provide the scientific community a valuable resource for structural biology research.

Contact PI: Xu, Karen.